Gene Saylors

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 249 citations · Full text

Hematological Malignancy, Oncology, Hematology +6

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol et al. · The Lancet Haematology · 2019 · 237 citations · Full text

Hematological Malignancy, Medicine, Immunology +7

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

Paul M. Barr, Gene Saylors, Stephen E. Spurgeon et al. · Blood · 2016 · 139 citations · Full text

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

Jonathan Spicer, Changli Wang, Fumihiro Tanaka et al. · Journal of Clinical Oncology · 2021 · 135 citations

Surgical Oncology, Cancer Management, Surgery +19

Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial

Patrick M. Forde, Jonathan Spicer, Shun Lü et al. · Cancer Research · 2021 · 98 citations

Surgical Oncology, Cancer Management, Multimodality +18